Role of multidrug transporters in neurotherapeutics

Annals of Indian Academy of Neurology

Volumn 12, Issue 2, 2009, Pages 89-98

  Jose, Manna ^a   Thomas, Sanjeev ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Drug resistant epilepsy; Multidrug resistance; Multidrug resistance protein; P glycoprotein; Teratogenic effect; Transport proteins

Indexed keywords

ABC TRANSPORTER; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; AZIDOPINE; CALMODULIN INHIBITOR; CYCLOSPORIN A; DILTIAZEM; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; QUININE DERIVATIVE; VALSPODAR; VERAPAMIL; XENOBIOTIC AGENT;

ALLELE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONGENITAL MALFORMATION; DNA POLYMORPHISM; EPILEPSY; HUMAN; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; NEUROLOGIC DISEASE; PLACENTA; PLACENTAL TRANSFER; REVIEW; TERATOGENICITY;

EID: 67749120544     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.53076     Document Type: Review

References (108)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
2. Riordan JR, Deuchars K, Kartner, N, Alon, N, Trent, J, Ling, V, 1985. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 31603, 817-9.
3. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989;9:1224-32.
4. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5:1922-7.
5. Lee G, Schlichter L, Bendayan M, Bendayan R. Functional Expression of P-glycoprotein in Rat Brain Microglia. Pharmacol Exp Ther 2001;299:204-12.
6. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
7. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000;92:1934-40.
8. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21-53.
9. Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 1995;131:137-50.
10. Mottino AD, Hoffman T, Jennes L, Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000;293:717-23.
11. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996;271:15091-8.
12. Schaub TP, Kartenbeck J, König J, Vogel O, Witzgall R, Kriz W, et al. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 1997;8:1213-21.
13. Schaub TP, Kartenbeck J, König J, Spring H, Dörsam J, Staehler G, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999;10:1159-69.
14. König J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999;29:1156-63.
15. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-9.
16. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, et al. Analysis of expression of cMOAT (MRP, MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP, in human cancer cell lines. Cancer Res 1997;57:3537-47.
17. Lee K, Belinsky MG, Bell DW, Testa JR, Kruh GD. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 1998;58:2741-7.
18. Belinsky MG, Bain LJ, Balsara BB, Testa JR, Kruh GD. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst 1998;90:1735-41.
19. Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 1999;59: 175-82.
20. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol 2000;57:634-41.
21. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD. Analysis of the structure and expression pattern of MRP7 (ABCC1, a new member of the MRP subfamily. Cancer Lett 2001;162:181-91.
22. Bera TK, Lee S, Salvatore G, Lee B, Pastan I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 2001;7:509-16.
23. Tammur J, Prades C, Arnould I, Rzhetsky A, Hutchinson A, Adachi M, et al. Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene 2001;273:89-96.
24. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 2001;33:503-11.
25. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
26. Dean M, Rzhetsky A, Allikmets R. The Human ATP-Binding Cassette (ABC) Transporter superfamily. Genome Res 2001;11:1156-66.
27. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006;44310:180-5.
28. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
29. Bakos E, Evers R, Szakács G, Tusnády GE, Welker E, Szabó K, et al. Functional multidrug resistance protein (MRP lacking the N-terminal transmembrane domain. J Biol Chem 1998;273:32167-75.
30. Gao M, Yamazaki M, Loe DW, Westlake CJ, Grant CE, Cole SP, et al. Multidrug resistance protein. Identification of regions required for active transport of leukotriene C4. J Biol Chem 1998;273:10733-40
31. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
32. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996;6:610-7.
33. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997;100:2430-6.
34. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
35. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-42.
36. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A 1992;89:8472-6.
37. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992;267:4854-8.
38. Scarborough GA. Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 1995;27:37-41.
39. Loo TW, Clarke DM. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem 2001;276:36877-80.
40. Qian YM, Qiu W, Gao M, Westlake CJ, Cole SP, Deeley RG. Characterization of binding of leukotriene C4 by human multidrug resistance protein 1: evidence of differential interactions with NH2- and COOH-proximal halves of the protein. J Biol Chem 2001;276:38636-44.
41. Szabó K, Welker E, Bakos Müller M, Roninson I, Váradi A, Sarkadi B. Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains. J Biol Chem 1998;273:10132-8.
42. Hrycyna CA, Ramachandra M, Ambudkar SV, Ko YH, Pedersen PL, Pastan I, et al. Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem 1998;273:16631-4.
43. Urbatsch IL, Tyndall GA, Tombline G, Senior AE. P glycoprotein catalytic mechanism: Studies of the ADP-vandalate inhibited state. J Biol Chem 2003;278:23171-9.
44. Bodó A, Bakos E, Szeri F, Váradi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003;11:140-1,133-43.
45. Shabbir A, DiStasio S, Zhao J, Cardozo CP, Wolff MS, Caplan AJ. Differential effects of the organochlorine pesticide DDT and its metabolite p,p'-DDE on P glycoprotein activity and expression. Toxicol Appl Pharmacol 2005;203:91-8.
46. Atkinson DE, Sibley CP, Boote V, Greenwood SL. MDR1 P-glycoprotein assay is severely affected by plastic derived xenobiotics. Placenta 2005;26:271-2.
47. Albertus JA, Laine RO. Enhanced xenobiotic transporter expression in normal teleost hepatocytes: response to environmental and chemotherapeutic toxins. J Exp Biol 2001;204:217-27.
48. Terasaki T, Ohtsuki S. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology. NeuroRx 2005;2:63-72.
49. Pleban K, Kopp S, Csaszar E, Peer M, Hrebicek T, Rizzi A, et al. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol 2005;67:365-74.
50. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985;31603:820-3.
51. Yasuhisa K, Michinori M, Kei T, Tohru S, Noriyuki K, Teruo A. ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein. Curr Drug Metab 2004;5:1-10.
52. Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A 2005;102:1933-8.
53. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986;23275:643-5.
54. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) 2004;173:132-8.
55. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
56. Hirrlinger J, König J, Keppler D, Lindenau J, Schulz JB, Dringen R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 2001;76:627-36.
57. Hirrlinger J, Schulz JB, Dringen R. Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res 2002;69:318-26.
58. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, et al. Coordinated induction of MRP/GS-X pump and -glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996;271:14981-8.
59. Yamane Y, Furuichi M, Song R, Van NT, Mulcahy RT, Ishikawa T, et al. Expression of multidrug resistance protein/GS-X pump and -glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem 1998;273:31075-85.
60. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Tien Kuo M. Differential sensitivities of the MRP gene family and -glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol 2001;61:555-63.
61. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC and related transporters. Toxicology 2001;167:3-23.
62. Rost D, Mahner S, Sugiyama Y, Stremmel W. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol Gastrointest Liver Physiol 2002;282:G720-6.
63. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC localized to the basolateral hepatocyte membrane. Hepatology 2003;38:374-84.
64. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000;97:7476-81.
65. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003;100:9244-9.
66. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003;278:17664-71.
67. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDRI" gene confers resistance to colchicine, doxorubicin, and vinblastine. PNAS 1987;84:3004-8.
68. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
69. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR gene and origin of P-glycoproteins. J Biol Chem 1990;265:506-14.
70. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
71. Germann UA, Schoenlein PV, Zimonjic DB, Popescu NC, Pastan I, Gottesman MM. Putative "MDR enhancer" is located on human chromosome 20 and not linked to the MDR1 gene on chromosome 7. Genes Chromosomes Cancer 1994;10:267-74.
72. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001;1:59-64.
73. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet 2002;47:38-50.
74. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo DM, Roma MI, et al. Ethnicity-Related Polymorphisms and Haplotypes in the Human ABCB1 Gene. Pharmacogenomics 2007;8:29-39.
75. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43:285-307.
76. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;35827:383-4.
77. Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy. Neurology 2005;642:S2-11.
78. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006;129:18-35.
79. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8.
80. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004;63:1090-2.
81. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004;63:1087-9.
82. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR gene and response to antiepileptic drug treatment. Epilepsia 2005;46:643-7.
83. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 2005;102:5507-12.
84. Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 2006;15:344-7.
85. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 2006;15:67-72.
86. Chen L, Liu CQ, Hu Y, Xiao ZT, Chen Y, Liao JX. Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 2007;9:11-4.
87. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, et al. The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res 2007;73:192-8.
88. Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol 2008;59:67-70.
89. Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 2002;43:1318-23.
90. Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004;2:37.
91. Ak H, Ay B, Tanriverdi T, Sanus GZ, Is M, Sar M, et al. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure 2007;16:493-503.
92. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007;115:232-42.
93. Sisodiya SM, Lin WR, Squier MV, Thom M. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;35724:42-3.
94. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
95. Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Leenstra, S, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118:417-29.
96. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-6.
97. Vogelgesang S, Kunert-Keil C, Cascorbi I, Mosyagin I, Schröder E, Runge U, et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 2004;23:223-31.
98. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000;279:R1495-503.
99. Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB. Pharmacogenetics 2004;14:309-18.
100. Kalabis GM, Kostaki A, Andrews MH, Petropoulos S, Gibb W, Matthews SG. Multidrug Resistance Phosphoglycoprotein (ABCB in the Mouse Placenta: Fetal Protection. Biol Reprod 2005;73:591-7.
101. Meyer Zu Schwabedissen HE, Grube M, Heydrich B, Linnemann K, Fusch C, Kroemer HK, et al. Expression, localization, and function of MRP5 (ABCC, a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation. Am J Pathol 2005;166:39-48.
102. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
103. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
104. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991;83:1386-91.
105. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein- mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 1992;89:5824-8.
106. Williams WC, Sinko PJ. Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Del Rev 1999;39:211-38.
107. Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18: 621-6.
108. Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: A review. J Chemother 2001;13:461-72.